Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ombrabulin

Known as: (2S)-2-amino-3-hydroxy-n-(2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)propanamide 
A synthetic water-soluble analogue of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Combination vascular-targeted therapies (VTTs) represent a promising approach for patients with platinum-resistant recurrent… Expand
  • table 1
  • table 2
  • table 2
  • table 3
  • table 3
Is this relevant?
2017
2017
2535 Background: O, a vascular-disrupting agent derived from combretastatin A4-phosphate, induces rapid tumor vascular shutdown… Expand
Is this relevant?
2015
2015
BACKGROUND Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour… Expand
Is this relevant?
2014
2014
BACKGROUND DISRUPT evaluated whether adding the vascular-disrupting agent ombrabulin to a taxane-platinum doublet in the first… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
SummaryPurpose Preclinical evidence supports synergy between the vascular disrupting agent ombrabulin and various chemotherapy… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2014
2014
Background:The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Nanomedicines have the potential to significantly impact cancer therapy by improving drug efficacy and decreasing off-target… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Purpose: The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
SummaryTargeting tumor vasculature is an emerging strategy in cancer treatment. Promising results have been shown in preclinical… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
3023 Background: Ob is a tubulin binding vascular disrupting agent, derivative of combretastatin A4. In preclinical studies… Expand
Is this relevant?